LENSAR, Inc. $LNSR Position Increased by Groupe la Francaise

Groupe la Francaise raised its stake in LENSAR, Inc. (NASDAQ:LNSR) by 99.5% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 251,400 shares of the company’s stock after buying an additional 125,400 shares during the period. Groupe la Francaise owned approximately 2.11% of LENSAR worth $3,311,000 as of its most recent filing with the SEC.

Several other large investors have also modified their holdings of LNSR. Brandes Investment Partners LP raised its position in shares of LENSAR by 3.5% during the second quarter. Brandes Investment Partners LP now owns 563,581 shares of the company’s stock worth $7,422,000 after purchasing an additional 18,894 shares during the period. Geode Capital Management LLC increased its stake in LENSAR by 103.9% in the 2nd quarter. Geode Capital Management LLC now owns 219,373 shares of the company’s stock worth $2,890,000 after purchasing an additional 111,802 shares in the last quarter. Credit Industriel ET Commercial raised its holdings in LENSAR by 98.4% during the 2nd quarter. Credit Industriel ET Commercial now owns 168,600 shares of the company’s stock worth $2,220,000 after buying an additional 83,600 shares during the period. DCF Advisers LLC lifted its stake in LENSAR by 1.3% during the second quarter. DCF Advisers LLC now owns 119,217 shares of the company’s stock valued at $1,570,000 after buying an additional 1,500 shares in the last quarter. Finally, OMERS ADMINISTRATION Corp purchased a new stake in LENSAR during the first quarter valued at about $1,680,000. 40.15% of the stock is owned by institutional investors.

LENSAR Stock Performance

LNSR stock opened at $10.49 on Thursday. The firm has a 50 day simple moving average of $11.35 and a 200 day simple moving average of $12.32. LENSAR, Inc. has a 52 week low of $7.13 and a 52 week high of $17.31. The stock has a market cap of $125.30 million, a P/E ratio of -2.39 and a beta of 0.66.

LENSAR (NASDAQ:LNSR) last released its earnings results on Thursday, November 6th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.23). The company had revenue of $14.32 million during the quarter, compared to analysts’ expectations of $17.75 million. LENSAR had a negative return on equity of 737.30% and a negative net margin of 87.12%.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on LNSR shares. Wall Street Zen upgraded shares of LENSAR to a “hold” rating in a report on Friday, November 28th. Weiss Ratings reiterated a “sell (d-)” rating on shares of LENSAR in a research report on Wednesday, October 8th. Two analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, LENSAR currently has a consensus rating of “Reduce” and an average price target of $15.00.

About LENSAR

LENSAR, Inc, a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. It offers LENSAR Laser System that incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision.